IGF signaling as a therapeutic target in pediatric solid tumors of the central and peripheral nervous system

References

• Datta SR, Dudek H, Tao X et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell91(2), 231–241 (1997).
   PubMed Web of Science ®Google Scholar
• Dudek H, Datta SR, Franke TF et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science275(5300), 661–665 (1997).
   PubMed Web of Science ®Google Scholar
• Okubo Y, Blakesley VA, Stannard B, Gutkind S, Le Roith D. Insulin-like growth factor-I inhibits the stress-activated protein kinase/c-Jun N-terminal kinase. J. Biol. Chem.273(40), 25961–25966 (1998).
   PubMed Web of Science ®Google Scholar
• Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene22(42), 6589–6597 (2003).
   PubMed Web of Science ®Google Scholar
• Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res.57(15), 3079–3083 (1997).
   PubMed Web of Science ®Google Scholar
• Benini S, Manara MC, Baldini N et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing’s sarcoma cells. Clin. Cancer Res.7(6), 1790–1797 (2001).
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Avnet S, Benini S et al. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing’s sarcoma cells. Int. J. Cancer101(1), 11–16 (2002).
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target: blocking transformation and inducing apoptosis. Curr. Cancer Drug Targets2(3), 191–207 (2002).
   PubMed Web of Science ®Google Scholar
• Adachi Y, Lee CT, Carbone DP. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy. Novartis Found Symp.262, 177–189 (2004).
   PubMedGoogle Scholar
• Guerreiro AS, Boller D, Doepfner KT, Arcaro A. IGF-IR: potential role in antitumor agents. Drug News Perspect.19(5), 261–272 (2006).
   PubMedGoogle Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer3(3), 203–216 (2003).
   PubMed Web of Science ®Google Scholar
• Riley RD, Heney D, Jones DR et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin. Cancer Res.10(1 Pt 1), 4–12 (2004).
   PubMed Web of Science ®Google Scholar
• Recio-Pinto E, Ishii DN. Effects of insulin, insulin-like growth factor-II and nerve growth factor on neurite outgrowth in cultured human neuroblastoma cells. Brain Res.302(2), 323–334 (1984).
   PubMed Web of Science ®Google Scholar
• Mattsson ME, Enberg G, Ruusala AI, Hall K, Pahlman S. Mitogenic response of human SH-SY5Y neuroblastoma cells to insulin-like growth factor I and II is dependent on the stage of differentiation. J. Cell. Biol.102(5), 1949–1954 (1986).
   PubMed Web of Science ®Google Scholar
• Mattsson ME, Hammerling U, Mohall E, Hall K, Pahlman S. Mitogenically uncoupled insulin and IGF-I receptors of differentiated human neuroblastoma cells are functional and mediate ligand-induced signals. Growth Factors2(4), 251–265 (1990).
   PubMed Web of Science ®Google Scholar
• Ota A, Wilson GL, Spilberg O, Pruss R, LeRoith D. Functional insulin-like growth factor I receptors are expressed by neural-derived continuous cell lines. Endocrinology122(1), 145–152 (1988).
   PubMed Web of Science ®Google Scholar
• Shemer J, Adamo M, Wilson GL, Heffez D, Zick Y, LeRoith D. Insulin and insulin-like growth factor-I stimulate a common endogenous phosphoprotein substrate (pp185) in intact neuroblastoma cells. J. Biol. Chem.262(32), 15476–15482 (1987).
   PubMed Web of Science ®Google Scholar
• El-Badry OM, Romanus JA, Helman LJ, Cooper MJ, Rechler MM, Israel MA. Autonomous growth of a human neuroblastoma cell line is mediated by insulin-like growth factor II. J. Clin. Invest.84(3), 829–839 (1989).
   PubMed Web of Science ®Google Scholar
• El-Badry OM, Helman LJ, Chatten J, Steinberg SM, Evans AE, Israel MA. Insulin-like growth factor II-mediated proliferation of human neuroblastoma. J. Clin. Invest.87(2), 648–657 (1991).
   PubMed Web of Science ®Google Scholar
• Yee D, Favoni RE, Lebovic GS et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J. Clin. Invest.86(6), 1806–1814 (1990).
   PubMed Web of Science ®Google Scholar
• Kuo YH, Chen TT. Novel activities of pro-IGF-I E peptides: regulation of morphological differentiation and anchorage-independent growth in human neuroblastoma cells. Exp. Cell. Res.280(1), 75–89 (2002).
   PubMed Web of Science ®Google Scholar
• Schneid H, Seurin D, Noguiez P, Le Bouc Y. Abnormalities of insulin-like growth factor (IGF-I and IGF-II) genes in human tumor tissue. Growth Regul.2(1), 45–54 (1992).
   PubMedGoogle Scholar
• Sullivan KA, Castle VP, Hanash SM, Feldman EL. Insulin-like growth factor II in the pathogenesis of human neuroblastoma. Am. J. Pathol.147(6), 1790–1798 (1995).
   PubMed Web of Science ®Google Scholar
• Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm. IGF Res.17(1), 54–57 (2007).
   PubMed Web of Science ®Google Scholar
• Martin DM, Feldman EL. Regulation of insulin-like growth factor-IL expression and its role in autocrine growth of human neuroblastoma cells. J. Cell. Physiol.155(2), 290–300 (1993).
   PubMed Web of Science ®Google Scholar
• Leventhal PS, Randolph AE, Vesbit TE, Schenone A, Windebank A, Feldman EL. Insulin-like growth factor-II as a paracrine growth factor in human neuroblastoma cells. Exp. Cell. Res.221(1), 179–186 (1995).
   PubMed Web of Science ®Google Scholar
• Maloney EK, McLaughlin JL, Dagdigian NE et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res.63(16), 5073–5083 (2003).
   PubMed Web of Science ®Google Scholar
• Kurihara S, Hakuno F, Takahashi S. Insulin-like growth factor-I-dependent signal transduction pathways leading to the induction of cell growth and differentiation of human neuroblastoma cell line SH-SY5Y: the roles of MAP kinase pathway and PI 3-kinase pathway. Endocr. J.47(6), 739–751 (2000).
   PubMed Web of Science ®Google Scholar
• Misawa A, Hosoi H, Tsuchiya K, Sugimoto T. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int. J. Cancer104(2), 233–237 (2003).
   PubMed Web of Science ®Google Scholar
• Kim B, van Golen CM, Feldman EL. Insulin-like growth factor-I signaling in human neuroblastoma cells. Oncogene23(1), 130–141 (2004).
   PubMed Web of Science ®Google Scholar
• Menouny M, Binoux M, Babajko S. Role of insulin-like growth factor binding protein-2 and its limited proteolysis in neuroblastoma cell proliferation: modulation by transforming growth factor-β and retinoic acid. Endocrinology138(2), 683–690 (1997).
   PubMed Web of Science ®Google Scholar
• Babajko S, Leneuve P, Loret C, Binoux M. IGF-binding protein-6 is involved in growth inhibition in SH-SY5Y human neuroblastoma cells: its production is both IGF- and cell density-dependent. J. Endocrinol.152(2), 221–227 (1997).
   PubMed Web of Science ®Google Scholar
• Kiess W, Koepf G, Christiansen H, Blum WF. Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul. Pept.72(1), 19–29 (1997).
   PubMedGoogle Scholar
• Russo VC, Rekaris G, Baker NL, Bach LA, Werther GA. Basic fibroblast growth factor induces proteolysis of secreted and cell membrane-associated insulin-like growth factor binding protein-2 in human neuroblastoma cells. Endocrinology140(7), 3082–3090 (1999).
   PubMed Web of Science ®Google Scholar
• Tanno B, Negroni A, Vitali R et al. Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms. J. Biol. Chem.277(26), 23172–23180 (2002).
   PubMed Web of Science ®Google Scholar
• Tanno B, Cesi V, Vitali R et al. Silencing of endogenous IGFBP-5 by micro RNA interference affects proliferation, apoptosis and differentiation of neuroblastoma cells. Cell Death Differ.12(3), 213–223 (2005).
   PubMed Web of Science ®Google Scholar
• Tanno B, Vitali R, De Arcangelis D et al. Bim-dependent apoptosis follows IGFBP-5 down-regulation in neuroblastoma cells. Biochem. Biophys. Res. Commun.351(2), 547–552 (2006).
   PubMed Web of Science ®Google Scholar
• Cesi V, Vitali R, Tanno B et al. Insulin-like growth factor binding protein 5: contribution to growth and differentiation of neuroblastoma cells. Ann. NY Acad. Sci.1028, 59–68 (2004).
   PubMed Web of Science ®Google Scholar
• Grellier P, De Galle B, Babajko S. Expression of insulin-like growth factor-binding protein 6 complementary DNA alters neuroblastoma cell growth. Cancer Res.58(8), 1670–1676 (1998).
   PubMed Web of Science ®Google Scholar
• Grellier P, Berrebi D, Peuchmaur M, Babajko S. The IGF system in neuroblastoma xenografts: focus on IGF-binding protein-6. J. Endocrinol.172(3), 467–476 (2002).
   PubMed Web of Science ®Google Scholar
• Seurin D, Lassarre C, Bienvenu G, Babajko S. Insulin-like growth factor binding protein-6 inhibits neuroblastoma cell proliferation and tumour development. Eur. J. Cancer38(15), 2058–2065 (2002).
   PubMed Web of Science ®Google Scholar
• Dake BL, Boes M, Bach LA, Bar RS. Effect of an insulin-like growth factor binding protein fusion protein on thymidine incorporation in neuroblastoma and rhabdomyosarcoma cell lines. Endocrinology145(7), 3369–3374 (2004).
   PubMed Web of Science ®Google Scholar
• Bach LA. IGFBP-6 five years on; not so ‘forgotten’? Growth Horm. IGF Res.15(3), 185–192 (2005).
   PubMed Web of Science ®Google Scholar
• Pahlman S, Meyerson G, Lindgren E, Schalling M, Johansson I. Insulin-like growth factor I shifts from promoting cell division to potentiating maturation during neuronal differentiation. Proc. Natl Acad. Sci. USA88(22), 9994–9998 (1991).
   PubMed Web of Science ®Google Scholar
• Lavenius E, Parrow V, Nanberg E, Pahlman S. Basic FGF and IGF-I promote differentiation of human SH-SY5Y neuroblastoma cells in culture. Growth Factors10(1), 29–39 (1994).
   PubMed Web of Science ®Google Scholar
• Sumantran VN, Feldman EL. Insulin-like growth factor I regulates c-myc and GAP-43 messenger ribonucleic acid expression in SH-SY5Y human neuroblastoma cells. Endocrinology132(5), 2017–2023 (1993).
   PubMed Web of Science ®Google Scholar
• Fagerstrom S, Pahlman S, Gestblom C, Nanberg E. Protein kinase C-e is implicated in neurite outgrowth in differentiating human neuroblastoma cells. Cell. Growth Differ.7(6), 775–785 (1996).
   PubMedGoogle Scholar
• Fagerstrom S, Pahlman S, Nanberg E. Protein kinase C-dependent tyrosine phosphorylation of p130cas in differentiating neuroblastoma cells. J. Biol. Chem.273(4), 2336–2343 (1998).
   PubMed Web of Science ®Google Scholar
• Kim B, Leventhal PS, Saltiel AR, Feldman EL. Insulin-like growth factor-I-mediated neurite outgrowth in vitro requires mitogen-activated protein kinase activation. J. Biol. Chem.272(34), 21268–21273 (1997).
   PubMed Web of Science ®Google Scholar
• Kim B, Leventhal PS, White MF, Feldman EL. Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells. Endocrinology139(12), 4881–4889 (1998).
   PubMed Web of Science ®Google Scholar
• Shiraishi M, Tanabe A, Saito N, Sasaki Y. Unphosphorylated MARCKS is involved in neurite initiation induced by insulin-like growth factor-I in SH-SY5Y cells. J. Cell. Physiol.209(3), 1029–1038 (2006).
   PubMed Web of Science ®Google Scholar
• Ma ZQ, Santagati S, Patrone C, Pollio G, Vegeto E, Maggi A. Insulin-like growth factors activate estrogen receptor to control the growth and differentiation of the human neuroblastoma cell line SK-ER3. Mol. Endocrinol.8(7), 910–918 (1994).
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Lucarelli E, Minniti C, Gaetano C, Thiele CJ. Signals transduced via insulin-like growth factor I receptor (IGF(R)) mediate resistance to retinoic acid-induced cell growth arrest in a human neuroblastoma cell line. Cell Death Differ.1(1), 49–58 (1994).
   PubMedGoogle Scholar
• Bernardini S, Cianfarani S, Spagnoli A et al. Expression and down-regulation by retinoic acid of IGF binding protein-2 and -4 in medium from human neuroblastoma cells. J. Neuroendocrinol.6(4), 409–413 (1994).
   PubMed Web of Science ®Google Scholar
• Chambery D, de Galle B, Babajko S. Retinoic acid stimulates IGF binding protein (IGFBP)-6 and depresses IGFBP-2 and IGFBP-4 in SK-N-SH human neuroblastoma cells. J. Endocrinol.159(2), 227–232 (1998).
   PubMed Web of Science ®Google Scholar
• Perez-Juste G, Aranda A. Differentiation of neuroblastoma cells by phorbol esters and insulin-like growth factor 1 is associated with induction of retinoic acid receptor β gene expression. Oncogene18(39), 5393–5402 (1999).
   PubMed Web of Science ®Google Scholar
• Zumkeller W, Schwab M. Insulin-like growth factor system in neuroblastoma tumorigenesis and apoptosis: potential diagnostic and therapeutic perspectives. Horm. Metab. Res.31(2–3), 138–141 (1999).
   PubMed Web of Science ®Google Scholar
• Matthews CC, Feldman EL. Insulin-like growth factor I rescues SH-SY5Y human neuroblastoma cells from hyperosmotic induced programmed cell death. J. Cell. Physiol.166(2), 323–331 (1996).
   PubMed Web of Science ®Google Scholar
• Singleton JR, Randolph AE, Feldman EL. Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res.56(19), 4522–4529 (1996).
   PubMed Web of Science ®Google Scholar
• Cheng HL, Feldman EL. Bidirectional regulation of p38 kinase and c-Jun N-terminal protein kinase by insulin-like growth factor-I. J. Biol. Chem.273(23), 14560–14565 (1998).
   PubMed Web of Science ®Google Scholar
• Brown A, Jolly P, Wei H. Genistein modulates neuroblastoma cell proliferation and differentiation through induction of apoptosis and regulation of tyrosine kinase activity and N-myc expression. Carcinogenesis19(6), 991–997 (1998).
   PubMed Web of Science ®Google Scholar
• Van Golen CM, Feldman EL. Insulin-like growth factor I is the key growth factor in serum that protects neuroblastoma cells from hyperosmotic-induced apoptosis. J. Cell. Physiol.182(1), 24–32 (2000).
   PubMed Web of Science ®Google Scholar
• Leinninger GM, Russell JW, van Golen CM, Berent A, Feldman EL. Insulin-like growth factor-I regulates glucose-induced mitochondrial depolarization and apoptosis in human neuroblastoma. Cell Death Differ.11(8), 885–896 (2004).
   PubMed Web of Science ®Google Scholar
• Gil-Ad I, Shtaif B, Luria D, Karp L, Fridman Y, Weizman A. Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture. Growth Horm. IGF Res.9(6), 458–464 (1999).
   PubMed Web of Science ®Google Scholar
• Liu X, Turbyville T, Fritz A, Whitesell L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res.58(23), 5432–5438 (1998).
   PubMed Web of Science ®Google Scholar
• van Golen CM, Castle VP, Feldman EL. IGF-I receptor activation and BCL-2 overexpression prevent early apoptotic events in human neuroblastoma. Cell Death Differ.7(7), 654–665 (2000).
   PubMed Web of Science ®Google Scholar
• Beierle EA, Strande LF, Chen MK. Insulin-like growth factor-I protects neuroblastoma against starvation-induced apoptosis and is associated with increased Bcl-2 expression. J. Pediatr. Surg.37(3), 472–476 (2002).
   PubMed Web of Science ®Google Scholar
• van Golen CM, Schwab TS, Ignatoski KM, Ethier SP, Feldman EL. PTEN/MMAC1 overexpression decreases insulin-like growth factor-I-mediated protection from apoptosis in neuroblastoma cells. Cell. Growth Differ.12(7), 371–378 (2001).
   PubMedGoogle Scholar
• Schwab TS, Madison BB, Grauman AR, Feldman EL. Insulin-like growth factor-I induces the phosphorylation and nuclear exclusion of forkhead transcription factors in human neuroblastoma cells. Apoptosis10(4), 831–840 (2005).
   PubMed Web of Science ®Google Scholar
• Kim B, Feldman EL. Insulin-like growth factor I prevents mannitol-induced degradation of focal adhesion kinase and Akt. J. Biol. Chem.277(30), 27393–27400 (2002).
   PubMed Web of Science ®Google Scholar
• Kim B, Oh S, van Golen CM, Feldman EL. Differential regulation of insulin receptor substrate-1 degradation during mannitol and okadaic acid induced apoptosis in human neuroblastoma cells. Cell Signal.17(6), 769–775 (2005).
   PubMed Web of Science ®Google Scholar
• van Golen CM, Soules ME, Grauman AR, Feldman EL. N-Myc overexpression leads to decreased β1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene22(17), 2664–2673 (2003).
   PubMed Web of Science ®Google Scholar
• Saeki M, Maeda S, Wada K, Kamisaki Y. Insulin-like growth factor-1 protects peroxynitrite-induced cell death by preventing cytochrome c-induced caspase-3 activation. J. Cell. Biochem.84(4), 708–716 (2002).
   PubMed Web of Science ®Google Scholar
• Kenchappa P, Yadav A, Singh G, Nandana S, Banerjee K. Rescue of TNFα-inhibited neuronal cells by IGF-1 involves Akt and c-Jun N-terminal kinases. J. Neurosci. Res.76(4), 466–474 (2004).
   PubMed Web of Science ®Google Scholar
• Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res.67(2), 735–745 (2007).
   PubMed Web of Science ®Google Scholar
• Leventhal PS, Shelden EA, Kim B, Feldman EL. Tyrosine phosphorylation of paxillin and focal adhesion kinase during insulin-like growth factor-I-stimulated lamellipodial advance. J. Biol. Chem.272(8), 5214–5218 (1997).
   PubMed Web of Science ®Google Scholar
• Kim B, Feldman EL. Differential regulation of focal adhesion kinase and mitogen-activated protein kinase tyrosine phosphorylation during insulin-like growth factor-I-mediated cytoskeletal reorganization. J. Neurochem.71(3), 1333–1336 (1998).
   PubMed Web of Science ®Google Scholar
• Kim B, Cheng HL, Margolis B, Feldman EL. Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling. J. Biol. Chem.273(51), 34543–34550 (1998).
   PubMed Web of Science ®Google Scholar
• Puglianiello A, Germani D, Rossi P, Cianfarani S. IGF-I stimulates chemotaxis of human neuroblasts. Involvement of type 1 IGF receptor, IGF binding proteins, phosphatidylinositol-3 kinase pathway and plasmin system. J. Endocrinol.165(1), 123–131 (2000).
   PubMed Web of Science ®Google Scholar
• Meyer GE, Shelden E, Kim B, Feldman EL. Insulin-like growth factor I stimulates motility in human neuroblastoma cells. Oncogene20(51), 7542–7550 (2001).
   PubMed Web of Science ®Google Scholar
• Meyer G, Kim B, van Golen C, Feldman EL. Cofilin activity during insulin-like growth factor I-stimulated neuroblastoma cell motility. Cell Mol. Life Sci.62(4), 461–470 (2005).
   PubMed Web of Science ®Google Scholar
• Meyer A, van Golen CM, Kim B, van Golen KL, Feldman EL. Integrin expression regulates neuroblastoma attachment and migration. Neoplasia6(4), 332–342 (2004).
   PubMed Web of Science ®Google Scholar
• van Golen CM, Schwab TS, Kim B et al. Insulin-like growth factor-I receptor expression regulates neuroblastoma metastasis to bone. Cancer Res.66(13), 6570–6578 (2006).
   PubMed Web of Science ®Google Scholar
• Beppu K, Nakamura K, Linehan WM, Rapisarda A, Thiele CJ. Topotecan blocks hypoxia-inducible factor-1α and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res.65(11), 4775–4781 (2005).
   PubMed Web of Science ®Google Scholar
• Chambery D, Mohseni-Zadeh S, de Galle B, Babajko S. N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line. Cancer Res.59(12), 2898–2902 (1999).
   PubMed Web of Science ®Google Scholar
• Jasty R, van Golen C, Lin HJ et al. Bcl-2 and M-Myc coexpression increases IGF-IR and features of malignant growth in neuroblastoma cell lines. Neoplasia3(4), 304–313 (2001).
   PubMed Web of Science ®Google Scholar
• Misawa A, Hosoi H, Arimoto A et al. N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res.60(1), 64–69 (2000).
   PubMed Web of Science ®Google Scholar
• Wittrock J, Schweizer P, Girgert R. Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors. Anticancer Res.22(6C), 4205–4209 (2002).
   PubMed Web of Science ®Google Scholar
• Kim CJ, Chi JG, Thiele CJ. Insulin-like growth factor-II expression is down-regulated in TrkA-transfected SK-N-AS neuroblastoma cells. Lab. Invest.79(8), 1007–1013 (1999).
   PubMed Web of Science ®Google Scholar
• Kim CJ, Matsuo T, Lee KH, Thiele CJ. Up-regulation of insulin-like growth factor-II expression is a feature of TrkA but not TrkB activation in SH-SY5Y neuroblastoma cells. Am. J. Pathol.155(5), 1661–1670 (1999).
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C, Pearson MA, Marti A et al. In vivo antitumor activity of NVP–AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell.5(3), 231–239 (2004).
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Mitsiades NS, McMullan CJ et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell.5(3), 221–230 (2004).
   PubMed Web of Science ®Google Scholar
• Guerreiro AS, Boller D, Shalaby T, Grotzer MA, Arcaro A. Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int. J. Cancer119(11), 2527–2538 (2006).
   PubMed Web of Science ®Google Scholar
• Tanno B, Mancini C, Vitali R et al. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin. Cancer Res.12(22), 6772–6780 (2006).
   PubMed Web of Science ®Google Scholar
• Meyer GE, Chesler L, Liu D et al. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J. Cell. Biochem. DOI: 10.1002/jcb.21373 (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Muller HL, Oh Y, Gargosky SE, Lehrnbecher T, Hintz RL, Rosenfeld RG. Concentrations of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3), IGF, and IGFBP-3 protease activity in cerebrospinal fluid of children with leukemia, central nervous system tumor, or meningitis. J. Clin. Endocrinol. Metab.77(5), 1113–1119 (1993).
   PubMed Web of Science ®Google Scholar
• Muller HL, Oh Y, Lehrnbecher T, Blum WF, Rosenfeld RG. Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J. Clin. Endocrinol. Metab.79(2), 428–434 (1994).
   PubMed Web of Science ®Google Scholar
• Patti R, Reddy CD, Geoerger B et al. Autocrine secreted insulin-like growth factor-I stimulates MAP kinase-dependent mitogenic effects in human primitive neuroectodermal tumor/medulloblastoma. Int. J. Oncol.16(3), 577–584 (2000).
   PubMed Web of Science ®Google Scholar
• Ogino S, Kubo S, Abdul-Karim FW, Cohen ML. Comparative immunohistochemical study of insulin-like growth factor II and insulin-like growth factor receptor type 1 in pediatric brain tumors. Pediatr. Dev. Pathol.4(1), 23–31 (2001).
   PubMed Web of Science ®Google Scholar
• Del Valle L, Enam S, Lassak A et al. Insulin-like growth factor I receptor activity in human medulloblastomas. Clin. Cancer Res.8(6), 1822–1830 (2002).
   PubMed Web of Science ®Google Scholar
• Wang JY, Del Valle L, Gordon J et al. Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene20(29), 3857–3868 (2001).
   PubMed Web of Science ®Google Scholar
• Ye P, Xing Y, Dai Z, D’Ercole AJ. In vivo actions of insulin-like growth factor-I (IGF-I) on cerebellum development in transgenic mice: evidence that IGF-I increases proliferation of granule cell progenitors. Brain Res. Dev. Brain Res.95, 44–54 (1996).
   PubMedGoogle Scholar
• Rao G, Pedone CA, Valle LD, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene23(36), 6156–6162 (2004).
   PubMed Web of Science ®Google Scholar
• Reiss K. Insulin-like growth factor-I receptor – a potential therapeutic target in medulloblastomas. Expert Opin. Ther. Targets6(5), 539–544 (2002).
   PubMedGoogle Scholar
• Urbanska K, Trojanek J, Del Valle L et al. Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3b constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines. Oncogene26(16), 2308–2317 (2007).
   PubMed Web of Science ®Google Scholar
• Rorke LB, Packer RJ, Biegel JA. Central nervous system atypical teratoid/rhabdoid tumors of infancy and childhood: definition of an entity. J. Neurosurg.85, 56–65 (1996).
   PubMed Web of Science ®Google Scholar
• Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am. J. Surg. Pathol.28(5), 644–650 (2004).
   PubMed Web of Science ®Google Scholar
• Biegel JA, Tan L, Zhang F, Wainwright L, Russo P, Rorke LB. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors. Clin. Cancer Res.8(11), 3461–3467 (2002).
   PubMed Web of Science ®Google Scholar
• Versteege I, Sevenet N, Lange J et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature394(6689), 203–206 (1998).
   PubMed Web of Science ®Google Scholar
• Burger PC, Yu IT, Tihan T et al. Atypical teratoid/rhabdoid tumor of the central nervous system: a highly malignant tumor of infancy and childhood frequently mistaken for medulloblastoma: a Pediatric Oncology Group study. Am. J. Surg. Pathol.22(9), 1083–1092 (1998).
   PubMed Web of Science ®Google Scholar
• Bambakidis NC, Robinson S, Cohen M, Cohen AR. Atypical teratoid/rhabdoid tumors of the central nervous system: clinical, radiographic and pathologic features. Pediatr. Neurosurg.37(2), 64–70 (2002).
   PubMed Web of Science ®Google Scholar
• Hilden JM, Meerbaum S, Burger P et al. Central nervous system atypical teratoid/rhabdoid tumor: results of therapy in children enrolled in a registry. J. Clin. Oncol.22(14), 2877–2884 (2004).
   PubMed Web of Science ®Google Scholar
• Tekautz TM, Fuller CE, Blaney S et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J. Clin. Oncol.23(7), 1491–1499 (2005).
   PubMed Web of Science ®Google Scholar
• D’Cunja J, Shalaby T, Rivera P et al. Antisense treatment of IGF-IR induces apoptosis and enhances chemosensitivity in central nervous system atypical teratoid/rhabdoid tumours cells. Eur. J. Cancer43(10), 1581–1589 (2007).
   PubMed Web of Science ®Google Scholar
• Arcaro A, Doepfner KT, Boller D et al. Novel role for insulin as an autocrine growth factor for malignant brain tumour cells. Biochem. J.406(1), 57–66 (2007).
   PubMed Web of Science ®Google Scholar
• Hayward R. The present and future management of childhood craniopharyngioma. Childs Nerv. Syst.15, 764–769 (1999).
   PubMed Web of Science ®Google Scholar
• Moore KD, Couldwell WT. Craniopharyngioma. In: Neuro-Oncology: The Essentials (1st Edition). Bernstein M, Berger MS (Eds). Thieme Medical Pub NY, USA 409–418 (2000).
   Google Scholar
• Bucher H, Zapf J, Torresani T, Prader A, Froesch ER, Illig R. Insulin-like growth factors I and II, prolactin, and insulin in 19 growth hormone-deficient children with excessive, normal, or decreased longitudinal growth after operation for craniopharyngioma. N. Engl. J. Med.309(19), 1142–1146 (1983).
   PubMed Web of Science ®Google Scholar
• Corneli G, Baldelli R, Di Somma C et al. Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. Growth Horm. IGF Res.13(2–3), 104–108 (2003).
   PubMed Web of Science ®Google Scholar
• Pinto G, Bussieres L, Recasens C, Souberbielle JC, Zerah M, Brauner R. Hormonal factors influencing weight and growth pattern in craniopharyngioma. Horm. Res.53(4), 163–169 (2000).
   PubMed Web of Science ®Google Scholar
• Chung TT, Drake WM, Evanson J et al. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. Clin. Endocrinol. (Oxf.)63(3), 274–279 (2005).
   PubMed Web of Science ®Google Scholar
• Wit JM, Schuitema-Dijkstra A, van Buul-Offers S, Opmeer F, Van den Brande JL. Excessive growth in a child with craniopharyngioma and growth hormone deficiency. Eur. J. Pediatr.147(6), 658–661 (1988).
   PubMed Web of Science ®Google Scholar
• Zumkeller W, Saaf M, Rahn T, Hall K. Demonstration of insulin-like growth factors I, II and heterogeneous insulin-like growth factor binding proteins in the cyst fluid of patients with craniopharyngioma. Neuroendocrinology54(3), 196–201 (1991).
   PubMed Web of Science ®Google Scholar
• Zumkeller W, Saaf M, Rahn T. Insulin-like growth factors and IGF binding proteins in cyst fluid from patients with craniopharyngioma prior to intracavitary irradiation with Yttrium and thereafter. Clin. Mol. Pathol.49(1), M51–M56 (1996).
   Google Scholar
• Ulfarsson E, Karstrom A, Yin S et al. Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin. Cancer Res.11(13), 4674–4680 (2005).
   PubMed Web of Science ®Google Scholar
• Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer Res.12(18), 5268–5272 (2006).
   PubMed Web of Science ®Google Scholar
• Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther.6(1), 1–12 (2007).
   PubMed Web of Science ®Google Scholar
• Laron Z. Laron-type dwarfism (hereditary somatomedin deficiency): a review. Ergeb Inn. Med. Kinderheilkd51, 117–150 (1984).
   PubMedGoogle Scholar
• Rosenbloom AL, Guevara Aguirre J, Rosenfeld RG, Fielder PJ. The little women of Loja – growth hormone-receptor deficiency in an inbred population of southern Ecuador. N. Engl. J. Med.323(20), 1367–1374 (1990).
   PubMed Web of Science ®Google Scholar
• Wittman MD, Balasubramanian B, Stoffan K et al. Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase. Bioorg. Med. Chem. Lett.17(4), 974–977 (2007).
   PubMed Web of Science ®Google Scholar
• Allen GW, Saba C, Armstrong EA et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res.67(3), 1155–1162 (2007).
   PubMed Web of Science ®Google Scholar
• Tazzari PL, Tabellini G, Bortul R et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia21(5), 886–896 (2007).
   PubMed Web of Science ®Google Scholar
• Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia21(9), 1921–1930 (2007).
   PubMed Web of Science ®Google Scholar